AzTrials
AzTrials

Heart FailureNCT05081947

Assessing the Acceptability and Feasibility of COMPASS

A study testing COMPASS in people with Heart Failure and Depression, run by King's College London at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Heart failure (HF) is a complex clinical syndrome characterized by the inability of the heart to pump an adequate amount of blood. Heart failure affects patients' ability to carry out even simple activities of daily living and therefore has a negative psychological impact. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Heart Failure, Depression, Anxiety
What is being tested?
COMPASS
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2 participants
Where
1 siteUnited Kingdom
Study dates
11 Nov 2021to 1 Apr 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Community-based HF patients from community HF service and outpatient department with depression and anxiety related to their HF will be invited to participate in the study. The inclusion criteria include:
  • Adults over 18 years of age;
  • community-based HF patients capable of providing written/verbal informed consent;
  • Community-based HF patients with mild to moderately-severe depression (using PHQ-9) with/without anxiety symptoms related to their HF;
  • community-based HF patients who are not engaging in any psychological treatment at the time of recruitment;
  • Is fluent in the English language so can fully respond to verbal and written material; and
  • Has access to the internet and has an electronic device (i.e. computer, laptop etc).

Who cannot join

  • The exclusion criteria include community-based HF patients:
  • With severe depression validated by PHQ-9 score (> 19) as assessed by the researcher;
  • who are receiving or engaging in other psychological treatment for anxiety and depression;
  • have active suicidal ideation if reported during the assessment with the researcher.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Heart Failure Community Service

    London, Westminester, SW1V 2QP

Other trials in United Kingdom

About this study

Official title: Assessing the Acceptability and Feasibility of COMPASS, a Transdiagnostic Web-based Intervention for the Management of Depression and Anxiety in Long-term Conditions, in Community-based Heart Failure Patients

Heart failure (HF) is a complex clinical syndrome characterized by the inability of the heart to pump an adequate amount of blood. Heart failure affects patients' ability to carry out even simple activities of daily living and therefore has a negative psychological impact. Many studies reported that anxiety and depression are prevalent among HF patients and it is being associated with high morbidity, mortality and costs. Community HF patients who are diagnosed with depression are usually referred for Improving Access for Psychological Therapies (IAPT). The IAPT services have long waiting lists and many patients in the community still do not have access to IAPT. IAPT (2017) found web-based interventions for psychological therapies for emotional disorders such as depression and anxiety to be as effective as the traditional interventions and yielded positive mental health outcomes.

In this current study, the feasibility and acceptability of the proposed COMPASS web-based intervention will be examined. COMPASS is a web-based therapy (online CBT program) designed for the management of depression and anxiety for patients with long term conditions such as heart failure.

This study will be conducted into three parts and mainly include one-to-one interviews. First, the researcher will use an approach called "think aloud" which is a specific type of interview that allows us to observe the participant while using the proposed COMPASS online using Microsoft Teams. The participant will be asked to log into the COMPASS website and talk to the researcher continuously as possible about what they are thinking or what comes into their mind as they are using the COMPASS website. Following this interview, the researcher will ask the participant to use COMPASS from any internet-connected device for four weeks with weekly follow-up telephone calls. One month after the completion of COMPASS, the researcher will interview the participants.

Read the detailed description

Heart failure (HF) is the inability of the heart muscle to pump enough blood to meet the body's blood and oxygen requirements. The European Society of Cardiology (ESC) described HF as a clinical syndrome resulting from the reduced cardiac output that may be accompanied with high intracardiac pressure during rest or with stress. It is characterized by shortness of breath, fatigue and limited exercise tolerance. The prevalence of HF is increasing worldwide, and HF cases increased by 23% in the United Kingdom (UK) from 2002 to 2014. In the year 2017-2018 in England, 500,000 people were diagnosed with heart failure. According to hospital diagnoses in the UK, there were up to 920,000 people living with HF. Many HF patients develop anxiety and depression due to the pathological similarities in both conditions. The prevalence of major in depression in HF is reported to be around 20-40% that is more than the reported prevalence in the normal population.

The National Institute for Health and Care Excellence (NICE) guidelines on HF emphasized the importance of treating depression in HF but there were no specific treatment options for HF recommended in the document. The ESC HF recommended initiating depression treatment for all HF patients using psychosocial interventions, pharmacological therapy or exercise training. In Southwark and Lambeth Boroughs, the community-based HF patients who are diagnosed with depression are usually referred for psychological treatment such as Improving Access for Psychological Therapies (IAPT) or 3 Dimensions for Long Term Conditions (3DLC). The type of treatment depends on the severity of their depression and the extent to which depression is affecting clients' self-management of HF. So, for persistent and mild to moderate depression or if the depression is not related to HF, the patients will be referred to IAPT for treatment. While, for moderately severe to severe depression and whose depression affects their management of HF, patients will be seen by the team of 3DLC. The IAPT services have long waiting lists and many patients in the community with anxiety and depression still do not have access to IAPT. The impact of the Covid-19 pandemic has increased the burden further on IAPTS services.

This current study builds on our phase 2 study (268951) which is currently using online focus group with community HF nurses (n=5) and qualitative telephone/online interviews with community-based HF patients (n=8) to examine their views and experiences in managing depression and anxiety in the primary setting, and whether the proposed COMPASS, a web-based intervention, can be used for managing depression and anxiety in community-based HF patients. The findings from phase 2 study will be analysed to identify patients' perspectives and readiness to use the web-based COMPASS intervention for managing anxiety and depression in HF.

In this study (phase 3), the feasibility and acceptability of the proposed COMPASS web-based intervention will be examined with community-based HF patients. Web-based interventions such as COMPASS are programs or applications that can be accessed through the website. They are usually developed to change health behaviour, provide education, monitor symptoms or deliver interventions. Barak et al. (2009) defined a web-based intervention as programs that are primarily self-guided and that are delivered online for people requiring health and mental health-related support. These interventions aim to improve knowledge or create awareness through the delivery of health-related content in an interactive web-based program.

IAPT (2017) found web-based interventions for psychological therapies for emotional disorders such as depression and anxiety to be as effective as the traditional interventions and yielded positive mental health outcomes. Web-based interventions allow the intervention to be delivered through a patient-centred approach that is strengthened by the support of trained therapist. With the rapid advancement in technology and the widespread use of the internet, web-based interventions have grown in popularity as they are seen as cost-effective, and easily accessible from a patient perspective (Murray, 2012). Web-based interventions aim to improve self-management skills of patients with chronic diseases such as cardiovascular diseases, diabetes, and arthritis. Web-based interventions for chronic cardiac conditions were reported to be cost-effective, easily accessible by participants through different devices (laptops, smartphones or computers), confidential, non-stigmatizing and acceptable. Patients can easily fit the web-based interventions into their daily life, and it can be easily approached by HF patients.

COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research that shows the benefit of combining mental and physical healthcare. COMPASS was developed by a team of experienced health psychology researchers and practitioners at King's College London. The structure and content of COMPASS are based on a systematic review to identify mechanisms of action which trigger and sustain symptoms of depression and/or anxiety in the context of LTCs. COMPASS is tailored to gain an understanding of the difficulties that LTC patients experience and provide information and tools on how to manage these.

COMPASS is different from other web-based talking therapy because it:

  • is tailored to treat low mood and anxiety in the context of living with one or more long-term conditions.
  • uses the latest research evidence to identify mechanisms known to trigger and sustain symptoms of low mood and anxiety in people with long-term conditions. These mechanisms are then targeted in the program.
  • has been co-developed by people with long-term conditions to improve its acceptability, utility and ease of use.

The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.

If the proposed COMPASS is found to be applicable to use in HF, this will help patients who are considered vulnerable and are shielding from, for example, the COVID-19 outbreak. During the pandemic, patients were unable to attend for psychological therapies that were conducted face to face, thus the use of COMPASS will assist in delivering the psychological intervention for a large number of patients anywhere and at any time. In this study, the acceptability and feasibility of COMPASS as a web-based intervention during the Covid-19 pandemic will be also explored as a virtual therapeutic intervention.

Being tested
COMPASS
Medical subject headings
Heart Failure, Depression, Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • COMPASSBehavioural

    COMPASS is a web-based intervention (online CBT program) that was developed for managing illness-related anxiety and depression in patients with long-term conditions (LTC) (https://compass-ltc.org/). An example of the patient login page can be viewed here: www.compass-southwark.co.uk. COMPASS aims to support people in managing the challenges of living with a long-term condition. COMPASS is based on research which shows the benefit of combining mental and physical healthcare. The proposed COMPASS program consists of 11 online sessions for patients to work through over approximately 12 weeks. The sessions can be worked through in any order the patient would like. The sessions are split into four quadrants - North, East, South and West - which explore different elements of managing the LTC challenges that were identified from the evidence-based systematic review. Sessions contain information, interactive tasks, goal setting and patient stories.

Study groups in NCT05081947
Study groupRoleWhat they receive
Heart failure patientsOtherpatients will try the Compass intervention
Receives: Behavioral: COMPASS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. COMPASS Acceptability and feasibility as measured by Treatment Acceptability/Adherence Scale (TAAS) and interviews

    TAAS is a 10 items self-reported scale rated on a 7- point Likert scale. Possible scores can range from 10 to 70, and higher scores are indicative of higher acceptability of treatment and greater anticipated ability to adhere to it.

    Measured: This will be measured at first Think aloud Interview (immediately after first use of compass)

  2. COMPASS Acceptability and feasibility as measured by Treatment Acceptability/Adherence Scale (TAAS) and interviews

    TAAS is a 10 items self-reported scale rated on a 7- point Likert scale. Possible scores can range from 10 to 70, and higher scores are indicative of higher acceptability of treatment and greater anticipated ability to adhere to it.

    Measured: This will be measured second time at week 4 follow up post Compass use

  3. Treatment usability using the System Usability Scale (SUS)

    SUS scores have a range of 0 to 100. SUS yields a single number representing a composite measure of the overall usability of the intervention being used.

    Measured: This will be measured at weekly basis at each session after using compass and for a total of 4 weeks

Secondary outcomes (2)
  1. changes in depression scores as measured by Patient Health Questionnaire-9 (PHQ-9)

    The score ranges from 0-27 with highre scores indicating sever deprssion

    Measured: every 2 weeks after using compass. First it will be measures at baseline (before compass) and then every 2 weeks.

  2. changes in anxiety score as measured by Generalised Anxoety Disorder-7 (GAD-7)

    The score ranges from 0-21 with highre scores indicating sever anxiety

    Measured: every 2 weeks after using compass. First it will be measures at baseline (before compass) and then every 2 weeks.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Oct 2021
  2. Study start11 Nov 2021
  3. Primary completion1 Apr 2022
  4. Study completion1 Apr 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
2 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05081947
Sponsor's protocol ID
288961
Status last verified
Sep 2021
First submitted
23 Sep 2021
Last updated
14 Oct 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing COMPASS in people with Heart Failure and Depression, run by King's College London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

COMPASS Acceptability and feasibility as measured by Treatment Acceptability/Adherence Scale (TAAS) and interviews (time frame: This will be measured at first Think aloud Interview (immediately after first use of compass)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in